Advertisement

Drugs

, Volume 79, Issue 18, pp 1937–1945 | Cite as

Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?

  • David F. Heigener
  • Martin ReckEmail author
Review Article

Abstract

Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be shown that immunotherapy works as consolidation after chemoradiotherapy in locally advanced disease if the tumours express PD-L1. A significant and meaningful survival benefit for consolidation with durvalumab after chemoradiotherapy compared to chemoradiotherapy alone was observed in the PACIFIC trial. In addition, there is a growing body of evidence that this treatment modality is also effective in a neoadjuvant setting in early stages, whereas the role as adjuvant treatment after surgery needs to be determined. The impact of combination therapies in non-metastatic stages—either neoadjuvant or adjuvant—needs to be evaluated in future trials. It is yet unclear whether PD-L1 and tumour mutational burden are predictive biomarkers as randomised trials are missing.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript

Conflict of interest

DFH received Travel Reimbursement and honoraria for Speeches and consultancy from Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, Merck Sharp & Dohme, Bristol Myers Squibb, Astra Zeneca, AbbVie and Takeda. MR received Travel Reimbursement and honoraria for Speeches and consultancy from Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, Merck Sharp & Dohme, Bristol Myers Squibb, Astra Zeneca, AbbVie, Amgen and Takeda.

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.  https://doi.org/10.3322/caac.21208.CrossRefPubMedGoogle Scholar
  2. 2.
    Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.  https://doi.org/10.1016/j.jtho.2015.09.009.CrossRefPubMedGoogle Scholar
  3. 3.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.CrossRefGoogle Scholar
  4. 4.
    Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17(3):473–83.  https://doi.org/10.1093/annonc/mdj117.CrossRefPubMedGoogle Scholar
  5. 5.
    Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol. 2008;26(35):5755–60.  https://doi.org/10.1200/jco.2008.17.7840.CrossRefPubMedGoogle Scholar
  6. 6.
    Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450–6.  https://doi.org/10.1200/JCO.2007.14.4824.CrossRefPubMedGoogle Scholar
  7. 7.
    Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660–6.  https://doi.org/10.1200/JCO.2014.60.0130.CrossRefPubMedGoogle Scholar
  8. 8.
    Attarwala H. TGN1412: from discovery to disaster. J Young Pharm. 2010;2(3):332–6.  https://doi.org/10.4103/0975-1483.66810.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78.  https://doi.org/10.1056/NEJMra1514296.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Heigener D, Reck M. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther. 2015;15(1):69–83.  https://doi.org/10.1586/14737140.2015.957187.CrossRefPubMedGoogle Scholar
  11. 11.
    Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;387(10027):1540–50.  https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMedGoogle Scholar
  12. 12.
    Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.  https://doi.org/10.1016/S0140-6736(16)32517-X.CrossRefPubMedGoogle Scholar
  13. 13.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.  https://doi.org/10.1056/NEJMoa1507643.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.  https://doi.org/10.1056/NEJMoa1504627.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.  https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMedGoogle Scholar
  16. 16.
    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non-small-cell lung cancer. J Thorac Oncol. 2019;12(11), Abstr. no. 14.01.Google Scholar
  17. 17.
    Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–51.  https://doi.org/10.1056/NEJMoa1810865.CrossRefPubMedGoogle Scholar
  18. 18.
    Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.  https://doi.org/10.1056/NEJMoa1801005.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12(2):403–7.  https://doi.org/10.1016/j.jtho.2016.10.007.CrossRefPubMedGoogle Scholar
  20. 20.
    Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.  https://doi.org/10.1056/NEJMoa1716948.CrossRefPubMedGoogle Scholar
  21. 21.
    Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019.  https://doi.org/10.1056/NEJMoa1910231.CrossRefPubMedGoogle Scholar
  22. 22.
    Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42.  https://doi.org/10.1200/JCO.2009.23.2272.CrossRefPubMedGoogle Scholar
  23. 23.
    Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.  https://doi.org/10.1016/S1470-2045(06)70804-X.CrossRefPubMedGoogle Scholar
  24. 24.
    Group NM, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77.  https://doi.org/10.1016/s0140-6736(10)60059-1.CrossRefGoogle Scholar
  25. 25.
    Shamp S, Biswas T. Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): an updated population based analysis. J Clin Oncol. 2018;36(15_suppl):8522.CrossRefGoogle Scholar
  26. 26.
    Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.  https://doi.org/10.1200/JCO.2009.26.2543.CrossRefPubMedGoogle Scholar
  27. 27.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.  https://doi.org/10.1016/S1470-2045(14)71207-0.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lilenbaum R, Samuels M, Wang X, Kong FM, Janne PA, Masters G, et al. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol. 2015;10(1):143–7.  https://doi.org/10.1097/JTO.0000000000000347.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–99.  https://doi.org/10.1158/2159-8290.CD-16-0577.CrossRefPubMedGoogle Scholar
  30. 30.
    Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–35.  https://doi.org/10.1016/S1470-2045(16)00099-1.CrossRefPubMedGoogle Scholar
  31. 31.
    Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64(12):4328–37.  https://doi.org/10.1158/0008-5472.CAN-04-0073.CrossRefPubMedGoogle Scholar
  32. 32.
    Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687–95.  https://doi.org/10.1172/JCI67313.CrossRefPubMedGoogle Scholar
  33. 33.
    Song WA, Zhou NK, Wang W, Chu XY, Liang CY, Tian XD, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010;5(4):510–6.CrossRefGoogle Scholar
  34. 34.
    Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7(5):825–32.  https://doi.org/10.1097/JTO.0b013e318247504a.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, et al. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013;8(2):222–8.  https://doi.org/10.1097/JTO.0b013e3182774108.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–86.  https://doi.org/10.1056/NEJMoa1716078.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kwiatkowski DJ, Rusch V, Chaft JE, Johnson B, Nicholas A, Wistuba I, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). J Clin Oncol. 2019;37(suppl):abstr. 8503.Google Scholar
  38. 38.
    Provencio M, Nadal E, Insa A, Garcia Campelo R, Rubio JC, Domine M, et al. NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): a phase II multicenter exploratory study—final data of patients who underwent surgical assessment. J Clin Oncol. 2019;37(suppl):abstr 8509.Google Scholar
  39. 39.
    Shu CA, Grigg C, Chiuzan C, Garofano R, Patel V, Hernandez S, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;36(suppl):abstr. 8532.Google Scholar
  40. 40.
    Cascone T, William WN, Weissferdt A, Lin H, Leung CH, Carter BW, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;37(Suppl):Abstr 8504.Google Scholar
  41. 41.
    Gray JE, Villegas AE, Daniel DB, Vicente D, Murakami S, Hui R, et al. Three-year overall survival update from the PACIFIC trial. J Clin Oncol. 2019;37(15_suppl):8526.Google Scholar
  42. 42.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.  https://doi.org/10.1056/NEJMoa1709937.CrossRefPubMedGoogle Scholar
  43. 43.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.  https://doi.org/10.1056/NEJMoa1809697.CrossRefPubMedGoogle Scholar
  44. 44.
    Durm G, Althouse S, Sadiq A, Jalal S, Jabbour S, Zon R, et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. J Clin Oncol. 2018;36(15_suppl):8500.CrossRefGoogle Scholar
  45. 45.
    Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124(2):271–7.  https://doi.org/10.1002/cncr.31043.CrossRefPubMedGoogle Scholar
  46. 46.
    Heigener D, Reck M. Advanced non- small cell lung cancer: the role of PD-L1 inhibitors. J Thorac Dis. 2018;10(Suppl 13):S1468–73.CrossRefGoogle Scholar
  47. 47.
    Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.  https://doi.org/10.1126/science.aaa8172.CrossRefPubMedGoogle Scholar
  48. 48.
    Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803.  https://doi.org/10.1016/S1470-2045(15)00054-6.CrossRefPubMedGoogle Scholar
  49. 49.
    Paz-Ares L, Luft A, Tafreshi A, Gumus M. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36(suppl):Abstr 105.CrossRefGoogle Scholar
  50. 50.
    Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.  https://doi.org/10.1056/NEJMoa1801946.CrossRefPubMedGoogle Scholar
  51. 51.
    Heigener D, Reck M. New approaches in immunotherapy. In: Peters S, Besse B, editors. New therapeutic strategies in lung cancer. Switzerland: Springer International Publishing; 2015.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pulmonary MedicineHelios Klinik SchleswigSchleswigGermany
  2. 2.University of Kiel, School of MedicineKielGermany
  3. 3.Department of OncologyLungenClinic GrosshansdorfGrosshansdorfGermany
  4. 4.Airway Research Center North in the German Center for Lung Research (DZL)GrosshansdorfGermany

Personalised recommendations